Program
Flurbiprofen
Also written as “flurbiprofen”, “Flurbiprofen tablet” and “Flurbiprofen 100 mg”.
Its studies are mostly in Pharyngitis · HIV Infections · Diabetes Mellitus, Type 2 · Anemia · Periodontitis, led by 7 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| GlaxoSmithKline | 40 open or running | phase 1since Mar 1, 2007 | Mar 1, 2007 | none ahead |
| Reckitt | 30 open or running | phase 3since Jan 13, 2010 | Jan 13, 2010 | none ahead |
| Bristol-Myers Squibb | 10 open or running | phase 1since Aug 26, 2014 | Aug 26, 2014 | none ahead |
| Dexcel Pharma Technologies | 10 open or running | phase 2since Dec 27, 2009 | Dec 27, 2009 | none ahead |
| Idorsia Pharmaceuticals | 10 open or running | phase 1since Feb 15, 2022 | Feb 15, 2022 | none ahead |
| Institut de Recherches Internationales Servier (I.R.I.S.) | 10 open or running | phase 1since Nov 14, 2025 | Nov 14, 2025 | none ahead |
| Teikoku Seiyaku | 10 open or running | phase 1since Jan 19, 2025 | Jan 19, 2025 | none ahead |
Also a collaborator on its studies: socrametrics-gmbh and hwi-pharma-services-gmbh.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Mar 1, 2007First study: phase 1 study in AnemiaNew to GlaxoSmithKlineGlaxoSmithKline · NCT00443170 · 90 enrolled · Australia
- Feb 1, 2008Phase 1 study in Diabetes Mellitus, Type 2GlaxoSmithKline · NCT00615212 · 23 enrolled · United States
- Jul 23, 2009Phase 1 study in Drug InteractionsGlaxoSmithKline · NCT00964106 · 87 enrolled · Korea, Republic of
- Dec 27, 2009Dexcel Pharma Technologies's first study: phase 2 study in PeriodontitisNew to Dexcel Pharma TechnologiesDexcel Pharma Technologies · NCT01040286 · Israel
- Jan 13, 2010Reckitt's first studies: 2 phase 3 studies in PharyngitisNew to ReckittReckitt · NCT01049334, NCT01048866
- Oct 22, 2013Phase 3 study in PharyngitisReckitt · NCT01986361 · 122 enrolled · United States
- Aug 26, 2014Bristol-Myers Squibb's first study: phase 1 study in Drug-drug Interaction StudyNew to Bristol-Myers SquibbBristol-Myers Squibb · NCT02227173 · 20 enrolled · United States
- Jun 5, 2020Phase 1 study in HIV InfectionsGlaxoSmithKline · NCT04425902 · 20 enrolled · United States
- Feb 15, 2022Idorsia Pharmaceuticals's first study: phase 1 study in HealthyNew to Idorsia PharmaceuticalsIdorsia Pharmaceuticals · NCT05254548 · 22 enrolled · Germany
- Jan 19, 2025Teikoku Seiyaku's first study: phase 1 study in HealthyNew to Teikoku SeiyakuTeikoku Seiyaku · NCT06823284 · 26 enrolled · Germany
- Nov 14, 2025Institut de Recherches Internationales Servier (I.R.I.S.)'s first study: phase 1 study in Healthy Adult ParticipantsNew to Institut de Recherches Internationales Servier (I.R.I.S.)Institut de Recherches Internationales Servier (I.R.I.S.) · NCT07235748 · 28 enrolled · United Kingdom
TargetBeta
“Cyclooxygenase inhibitor; Cyclooxygenase inhibitor”ChEMBL 37, by rule
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Acetaminophenrule | Johnson & Johnson | phase 4 | 136 |
| Ibuprofenrule | Pfizer | phase 4 | 113 |
| Aspirinrule | Bayer | phase 4 | 84 |
| dexketoprofenrule | Menarini Group | phase 4 | 8 |
| Sulfasalazinerule | Bristol-Myers Squibb | phase 4 | 7 |
| dexibuprofenrule | aponia-laboratories-inc | phase 4 | 6 |
| Benzydaminerule | Angelini Pharma | phase 4 | 4 |
| Dipyronerule | Hypera Pharma | phase 4 | 4 |
| Piroxicamrule | Taisho Pharmaceutical | phase 4 | 4 |
Studies
All 12 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07235748Healthy Adult Participants · United Kingdom | 1 | Completed | Institut de Recherches Internationales Servier (I.R.I.S.) | Dec 23, 2025 | 28 |
| NCT06823284Healthy · Germany | 1 | Completed | Teikoku Seiyaku | Feb 12, 2025 | 26 |
| NCT05254548Healthy · Germany | 1 | Completed | Idorsia Pharmaceuticals | Apr 13, 2022 | 22 |
| NCT04425902HIV Infections · United States | 1 | Completed | GlaxoSmithKline | Mar 10, 2021 | 20 |
| NCT02227173Drug-drug Interaction Study · United States | 1 | Completed | Bristol-Myers Squibb | Nov 2014 | 20 |
| NCT01986361Pharyngitis · United States | 3 | Completed | Reckitt | Apr 2014 | 122 |
| NCT01049334Pharyngitis · United States | 3 | Completed | Reckitt | Mar 2011 | 204 |
| NCT01048866Pharyngitis · United States | 3 | Completed | Reckitt | Mar 2011 | 198 |
| NCT01040286Periodontitis · Israel | 2 | Completed | Dexcel Pharma Technologies | ||
| NCT00964106Drug Interactions · Korea, Republic of | 1 | Completed | GlaxoSmithKline | Aug 29, 2011 | 87 |
| NCT00615212Diabetes Mellitus, Type 2 · United States | 1 | Completed | GlaxoSmithKline | Feb 15, 2008 | 23 |
| NCT00443170Anemia · Australia | 1 | Completed | GlaxoSmithKline | 90 |
How it is read
Names in the registry
- “Flurbiprofen”, 7 entries
- “flurbiprofen”, 2 entries
- “Flurbiprofen tablet”, 1 entry
- “Flurbiprofen 100 mg”, 1 entry
- “omeprazole, caffeine, flurbiprofen, rosiglitazone”, 1 entry
Conditions, from the studies’ own filings
- Pharyngitis, 3 studies
- HIV Infections, 1 study
- Diabetes Mellitus, Type 2, 1 study
- Anemia, 1 study
- Periodontitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.